PortalPublikationenImpact of Donor Epstein-Barr Virus Serostatus on the Inciden...

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation

Standard

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. / Styczynski, Jan; Tridello, Gloria; Gil, Lidia; Ljungman, Per; Hoek, Jennifer; Iacobelli, Simona; Ward, Katherine N; Cordonnier, Catherine; Einsele, Hermann; Socie, Gerard; Milpied, Noel; Veelken, Hendrik; Chevallier, Patrice; Yakoub-Agha, Ibrahim; Maertens, Johan; Blaise, Didier; Cornelissen, Jan; Michallet, Mauricette; Daguindau, Etienne; Petersen, Eefke; Passweg, Jakob; Greinix, Hildegard; Duarte, Rafael F; Kröger, Nicolaus; Dreger, Peter; Mohty, Mohamad; Nagler, Arnon; Cesaro, Simone.

in: J CLIN ONCOL, Jahrgang 34, Nr. 19, 01.07.2016, S. 2212-20.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Styczynski, J, Tridello, G, Gil, L, Ljungman, P, Hoek, J, Iacobelli, S, Ward, KN, Cordonnier, C, Einsele, H, Socie, G, Milpied, N, Veelken, H, Chevallier, P, Yakoub-Agha, I, Maertens, J, Blaise, D, Cornelissen, J, Michallet, M, Daguindau, E, Petersen, E, Passweg, J, Greinix, H, Duarte, RF, Kröger, N, Dreger, P, Mohty, M, Nagler, A & Cesaro, S 2016, 'Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation', J CLIN ONCOL, Jg. 34, Nr. 19, S. 2212-20. https://doi.org/10.1200/JCO.2015.64.2405

APA

Styczynski, J., Tridello, G., Gil, L., Ljungman, P., Hoek, J., Iacobelli, S., Ward, K. N., Cordonnier, C., Einsele, H., Socie, G., Milpied, N., Veelken, H., Chevallier, P., Yakoub-Agha, I., Maertens, J., Blaise, D., Cornelissen, J., Michallet, M., Daguindau, E., ... Cesaro, S. (2016). Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. J CLIN ONCOL, 34(19), 2212-20. https://doi.org/10.1200/JCO.2015.64.2405

Vancouver

Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S et al. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. J CLIN ONCOL. 2016 Jul 1;34(19):2212-20. https://doi.org/10.1200/JCO.2015.64.2405

Bibtex

@article{ad10fc8f5e8a4d4f8552f855e5678532,
title = "Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation",
abstract = "PURPOSE: We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).PATIENTS AND METHODS: The study included 11,364 patients who underwent allogeneic peripheral-blood or bone marrow transplantation for acute leukemia between 1997 and 2012. We analyzed the impact of donor and recipient EBV serologic status on overall survival, relapse-free survival, relapse incidence, nonrelapse mortality, and incidence of graft-versus-host disease (GVHD) after allo-HSCT.RESULTS: Patients receiving grafts from EBV-seropositive donors had the same overall survival as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.97 to 1.12; P = .23). Seropositive donors also had no influence on relapse-free survival (HR, 1.04; 95% CI, 0.97 to 1.11; P = 0.31), relapse incidence (HR, 1.03; 95% CI, 0.94 to 1.12; P = .58), and nonrelapse mortality (HR, 1.05; 95% CI, 0.94 to 1.17; P = .37). However, in univariate analysis, recipients receiving grafts from seropositive donors had a higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .001; HR, 1.42; 95% CI, 1.30 to 1.56). When adjusting for confounders, higher risk was identified for both acute and chronic GVHD. In seronegative patients with seropositive donors, the HR for chronic GVHD was 1.30 (95% CI, 1.06 to 1.59; P = .039). In seropositive patients with seropositive donors, the HR was 1.24 (95% CI, 1.07 to 1.45; P = .016) for acute GVHD and 1.43 (95% CI, 1.23 to 1.67; P < .001) for chronic GVHD. Seropositive patients with seronegative donors did not have an increased risk of GVHD.CONCLUSION: Our data suggest that donor EBV status significantly influences development of acute and chronic GVHD after allo-HSCT.",
keywords = "Adolescent, Adult, Aged, Antibodies, Viral, Child, Child, Preschool, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Herpesvirus 4, Human, Humans, Incidence, Infant, Leukemia, Myeloid, Acute, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Tissue Donors, Journal Article",
author = "Jan Styczynski and Gloria Tridello and Lidia Gil and Per Ljungman and Jennifer Hoek and Simona Iacobelli and Ward, {Katherine N} and Catherine Cordonnier and Hermann Einsele and Gerard Socie and Noel Milpied and Hendrik Veelken and Patrice Chevallier and Ibrahim Yakoub-Agha and Johan Maertens and Didier Blaise and Jan Cornelissen and Mauricette Michallet and Etienne Daguindau and Eefke Petersen and Jakob Passweg and Hildegard Greinix and Duarte, {Rafael F} and Nicolaus Kr{\"o}ger and Peter Dreger and Mohamad Mohty and Arnon Nagler and Simone Cesaro",
note = "{\textcopyright} 2016 by American Society of Clinical Oncology.",
year = "2016",
month = jul,
day = "1",
doi = "10.1200/JCO.2015.64.2405",
language = "English",
volume = "34",
pages = "2212--20",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

RIS

TY - JOUR

T1 - Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation

AU - Styczynski, Jan

AU - Tridello, Gloria

AU - Gil, Lidia

AU - Ljungman, Per

AU - Hoek, Jennifer

AU - Iacobelli, Simona

AU - Ward, Katherine N

AU - Cordonnier, Catherine

AU - Einsele, Hermann

AU - Socie, Gerard

AU - Milpied, Noel

AU - Veelken, Hendrik

AU - Chevallier, Patrice

AU - Yakoub-Agha, Ibrahim

AU - Maertens, Johan

AU - Blaise, Didier

AU - Cornelissen, Jan

AU - Michallet, Mauricette

AU - Daguindau, Etienne

AU - Petersen, Eefke

AU - Passweg, Jakob

AU - Greinix, Hildegard

AU - Duarte, Rafael F

AU - Kröger, Nicolaus

AU - Dreger, Peter

AU - Mohty, Mohamad

AU - Nagler, Arnon

AU - Cesaro, Simone

N1 - © 2016 by American Society of Clinical Oncology.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - PURPOSE: We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).PATIENTS AND METHODS: The study included 11,364 patients who underwent allogeneic peripheral-blood or bone marrow transplantation for acute leukemia between 1997 and 2012. We analyzed the impact of donor and recipient EBV serologic status on overall survival, relapse-free survival, relapse incidence, nonrelapse mortality, and incidence of graft-versus-host disease (GVHD) after allo-HSCT.RESULTS: Patients receiving grafts from EBV-seropositive donors had the same overall survival as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.97 to 1.12; P = .23). Seropositive donors also had no influence on relapse-free survival (HR, 1.04; 95% CI, 0.97 to 1.11; P = 0.31), relapse incidence (HR, 1.03; 95% CI, 0.94 to 1.12; P = .58), and nonrelapse mortality (HR, 1.05; 95% CI, 0.94 to 1.17; P = .37). However, in univariate analysis, recipients receiving grafts from seropositive donors had a higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .001; HR, 1.42; 95% CI, 1.30 to 1.56). When adjusting for confounders, higher risk was identified for both acute and chronic GVHD. In seronegative patients with seropositive donors, the HR for chronic GVHD was 1.30 (95% CI, 1.06 to 1.59; P = .039). In seropositive patients with seropositive donors, the HR was 1.24 (95% CI, 1.07 to 1.45; P = .016) for acute GVHD and 1.43 (95% CI, 1.23 to 1.67; P < .001) for chronic GVHD. Seropositive patients with seronegative donors did not have an increased risk of GVHD.CONCLUSION: Our data suggest that donor EBV status significantly influences development of acute and chronic GVHD after allo-HSCT.

AB - PURPOSE: We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).PATIENTS AND METHODS: The study included 11,364 patients who underwent allogeneic peripheral-blood or bone marrow transplantation for acute leukemia between 1997 and 2012. We analyzed the impact of donor and recipient EBV serologic status on overall survival, relapse-free survival, relapse incidence, nonrelapse mortality, and incidence of graft-versus-host disease (GVHD) after allo-HSCT.RESULTS: Patients receiving grafts from EBV-seropositive donors had the same overall survival as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.97 to 1.12; P = .23). Seropositive donors also had no influence on relapse-free survival (HR, 1.04; 95% CI, 0.97 to 1.11; P = 0.31), relapse incidence (HR, 1.03; 95% CI, 0.94 to 1.12; P = .58), and nonrelapse mortality (HR, 1.05; 95% CI, 0.94 to 1.17; P = .37). However, in univariate analysis, recipients receiving grafts from seropositive donors had a higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .001; HR, 1.42; 95% CI, 1.30 to 1.56). When adjusting for confounders, higher risk was identified for both acute and chronic GVHD. In seronegative patients with seropositive donors, the HR for chronic GVHD was 1.30 (95% CI, 1.06 to 1.59; P = .039). In seropositive patients with seropositive donors, the HR was 1.24 (95% CI, 1.07 to 1.45; P = .016) for acute GVHD and 1.43 (95% CI, 1.23 to 1.67; P < .001) for chronic GVHD. Seropositive patients with seronegative donors did not have an increased risk of GVHD.CONCLUSION: Our data suggest that donor EBV status significantly influences development of acute and chronic GVHD after allo-HSCT.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antibodies, Viral

KW - Child

KW - Child, Preschool

KW - Female

KW - Graft vs Host Disease

KW - Hematopoietic Stem Cell Transplantation

KW - Herpesvirus 4, Human

KW - Humans

KW - Incidence

KW - Infant

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Middle Aged

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Tissue Donors

KW - Journal Article

U2 - 10.1200/JCO.2015.64.2405

DO - 10.1200/JCO.2015.64.2405

M3 - SCORING: Journal article

C2 - 27091716

VL - 34

SP - 2212

EP - 2220

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 19

ER -